Physician profile
Patrick S Freeman
NPI 1710959382
$2,888.39
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,408 · 2020: $203 · 2021: $64.57 · 2022: $32.24 · 2023: $917 · 2024: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,060 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,060.29 |
| Education | $119.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $584.52 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $315.67 | 2019-2023 | Farxiga, Breztri |
| Amarin Pharma, INC. | $220.52 | 2019-2020 | |
| Pfizer INC. | $218.17 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.98 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $160.14 | 2019-2024 | |
| Glaxosmithkline, LLC. | $137.66 | 2019-2023 | Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $119.05 | 2019-2024 | Trintellix |
| Astellas Pharma US INC | $112.96 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $108.57 | 2019-2020 | |
| Lilly USA, LLC | $93.53 | 2020-2024 | Mounjaro |
| Merck Sharp & Dohme LLC | $89.02 | 2019-2020 | |
| Amgen INC. | $66.63 | 2019 | |
| Idorsia Pharmaceuticals US INC | $64.99 | 2022-2023 | Quviviq |
| Welch Allyn | $64.57 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $48.38 | 2019 | |
| Gilead Sciences, INC. | $39.68 | 2019 | |
| Allergan, INC. | $36.29 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.45 | 2019-2022 | |
| Genentech USA, INC. | $26.02 | 2019 | |
| Inspire Medical Systems, INC. | $24.67 | 2023 | Inspire |
| Azurity Pharmaceuticals, INC. | $24.62 | 2023 | Edarbi |
| Lupin INC. | $23.63 | 2019 | |
| Dynavax Technologies Corporation | $23.57 | 2023 | Heplisav-B |
| Qol Medical, LLC | $17.86 | 2019 | |
| Dexcom, INC. | $16.57 | 2023 | Dexcom G6 Transmitter |
| Nalpropion Pharmaceuticals LLC | $13.15 | 2019 | |
| Currax Pharmaceuticals LLC | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.